Visfatin associated with major adverse cardiovascular events in patients with acute myocardial infarction.

ABSTRACT:

Background

Visfatin is an adipokine that related with the inflammation in atherosclerosis and the destabilization of atherosclerotic plaque. The aim of this study was to observe the relationship between visfatin and major adverse cardiovascular events (MACEs) in acute myocardial infarction (AMI) patients.

Methods

We enrolled a total of 238 patients (183 AMI and 55 control) who underwent coronary angiography. Patients with AMI were followed for an average of 19.3 months and 159 patients were finally included in the study.

Results

It was observed patients with AMI had higher serum visfatin levels than controls. The total incidence of MACEs was 11.32% (18/159) in AMI patients. After calculation of the Youden index, the best cut-off value of visfatin on the curve of recei

SUBMITTER: Zheng M 

PROVIDER: S-EPMC7275306 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature